Document:

Exhibit 10.9

 

indemnification
agreement

 

THIS INDEMNIFICATION AGREEMENT (the
 “Agreement”), dated as of ________ ___, 2020, is entered into by and between NeoGames S.A, a Luxembourg company
having its registered office at 5, rue de Bonnevoie, L-1260 Luxembourg, Grand Duchy of Luxembourg and registered with the Luxembourg
Trade and Company Register number R.C.S. Luxembourg B 186309 (the “Company”), and the undersigned Director or
Officer of the Company whose name appears on the signature page attached hereto (the “Indemnitee”).

 

		WHEREAS,	Indemnitee is an officer or director of the Company (“Office
Holder”); 

 

		WHEREAS,	both the Company and Indemnitee recognize the increased risk
of litigation and other claims being asserted against Office Holders of companies and that highly competent persons have become
more reluctant to serve corporations as directors and officers or in other capacities unless they are provided with adequate protection
through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their
service to, and activities on behalf of, companies; 

 

		WHEREAS,	the Amended and Restated Articles of Association of the Company
(the “Articles”) authorize the Company to indemnify and advance expenses to
its Office Holders and provide for insurance to its Office Holders, in each case, to the fullest extent permitted by applicable
law, and this Agreement is provided to Indemnitee in accordance with applicable law, the Articles and all requisite corporate approvals;

 

		WHEREAS,	the Company has determined that (i) the increased difficulty
in attracting and retaining competent persons is detrimental to the best interests of the Company’s shareholders and that
the Company should act to assure such persons that there will be increased certainty of such protection in the future, and (ii)
it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, and to advance expenses
on behalf of, such persons to the fullest extent permitted by applicable law, so that they will serve or continue to serve the
Company free from undue concern that they will not be so indemnified;

 

		WHEREAS,	the Company acknowledges that Indemnitee is relying on the obligations
of the Company set forth in this Agreement in agreeing to serve the Company, which obligations are therefore irrevocable; and

 

		WHEREAS,	in recognition of Indemnitee’s need for substantial protection
against loss arising from the Indemnitee’s liability, including costs and expenses incurred by the Indemnitee due to his
or her position as an Office Holder, in order to assure Indemnitee’s continued service to the Company in an effective manner
and, in part, in order to provide Indemnitee with specific contractual assurance that the indemnification and insurance afforded
by the Articles will be available to Indemnitee, the Company wishes to undertake in this Agreement for the indemnification of and
the advancing of expenses to Indemnitee to the fullest extent permitted by applicable law and as set forth in this Agreement and
provide for insurance of Indemnitee as set forth in this Agreement.

 

NOW, THEREFORE, the parties hereto
agree as follows:

 

		1.	INDEMNIFICATION AND INSURANCE.

 

		1.1.	The Company hereby undertakes
                                         to indemnify Indemnitee to the fullest extent permitted by applicable law and the Articles,
                                         as each may be amended from time to time, for any liability and expense specified in
                                         Sections ‎1.1.1 through ‎1.1.4 below, imposed on Indemnitee due to or in
                                         connection with an act performed by such Indemnitee, either prior to or after the date
                                         hereof, in Indemnitee’s capacity as an Office Holder, including, without limitation,
                                         as a director, officer, employee, agent, observer or fiduciary of the Company, any subsidiary
                                         thereof or any other corporation, collaboration, partnership, joint venture, trust or
                                         other enterprise, in which Indemnitee serves at any time at the request of the Company
                                         (the “Corporate Capacity”). The term “act performed in Indemnitee’s
                                         capacity as an Office Holder” shall include, without limitation, any act, omission
                                         and failure to act and any other circumstances relating to or arising from Indemnitee’s
                                         service in a Corporate Capacity. Notwithstanding the foregoing, in the event that the
                                         Office Holder is the beneficiary of an indemnification undertaking provided by a subsidiary
                                         of the Company or any other entity, with respect to his
                                         or her Corporate Capacity with such subsidiary or entity, then the indemnification obligations
                                         of the Company hereunder with respect to such Corporate Capacity shall only apply to
                                         the extent that the indemnification by such subsidiary or other entity does not actually
                                         fully cover the indemnifiable liabilities and expenses relating thereto. The following
                                         shall be hereinafter referred to as “Indemnifiable Events”:

 

     

    - 2 -

    

 

		1.1.1.	a financial liability imposed on Indemnitee in favor of another person by any court judgment, including
a judgment given as a result of a settlement or an arbitrator’s award which has been confirmed by a court in respect of an
act performed by the Indemnitee. For purposes of Section ‎1 of this Agreement, the term “person” shall
include, without limitation, a natural person, firm, partnership, joint venture, trust, company, corporation, limited liability
entity, unincorporated organization, estate, government, municipality, or any political, governmental, regulatory or similar agency
or body;

 

		1.1.2.	reasonable Expenses (as defined below) expended by Indemnitee as a result of an investigation or
proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that
(1) no indictment was filed against such Indemnitee as a result of such investigation or proceeding; and (2) no financial liability
in lieu of a criminal proceeding was imposed upon him or her as a result of such investigation or proceeding or if such financial
liability was imposed, it was imposed with respect to an offence that does not require proof of criminal intent, or in connection
with a financial sanction;

 

		1.1.3.	reasonable Expenses expended by Indemnitee or that were imposed on Indemnitee by a court in a proceeding
filed against the Indemnitee by the Company or in its name or by any other person or in a criminal charge in respect of which the
Indemnitee was acquitted or in a criminal charge in respect of which the Indemnitee was convicted for an offence that does not
require proof of criminal intent;

 

		1.1.4.	a financial liability imposed upon Indemnitee and reasonable Expenses expended by Indemnitee as
a result of an administrative proceeding instituted against Indemnitee; and

 

		1.1.5.	any other event, occurrence, matter or circumstance under any law with respect to which the Company
may, or will be able to, indemnify the Indemnitee.

 

For the purpose of this Agreement,
 “Expenses” shall include, without limitation, attorneys’ fees and all other costs, expenses and obligations
paid or incurred by Indemnitee in connection with investigating, defending, being a witness in or participating in (including on
appeal), or preparing to defend, be a witness in or participate in any claim, action, suit, proceeding, alternative dispute resolution
mechanism, hearing, inquiry or investigation relating to any matter for which indemnification hereunder may be provided, and costs
and expenses paid or incurred by Indemnitee in successfully enforcing this Agreement. Expenses shall be considered paid or incurred
by Indemnitee at such time as Indemnitee is required to pay or incur such cost or expenses, including upon receipt of an invoice
or payment demand. The Company shall pay the Expenses in accordance with the provisions of Section ‎1.2.

 

     

    - 3 -

    

 

		1.2.	If so requested by Indemnitee, and subject to the Company’s repayment and reimbursement rights
set forth in Sections 3 and 5 below, the Company shall pay amounts to cover Indemnitee’s Expenses with respect to which Indemnitee
is entitled to be indemnified under Section ‎1.1 above, as and when incurred. The payments of such amounts shall be made
by the Company directly to the Indemnitee’s legal and other advisors, as soon as practicable, but in any event no later than
fifteen (15) days after written demand by such Indemnitee therefor to the Company, and any such payment shall be deemed to constitute
indemnification hereunder. All amounts paid as indemnification hereunder shall be grossed up to cover any tax payment that Indemnitee
may be required to make if the indemnification payments are taxable, subject to the Limit Amount if required by applicable law.
As part of the aforementioned undertaking, the Company will make available to Indemnitee any security or guarantee that Indemnitee
may be required to post in accordance with an interim decision given by a court, governmental or administrative body, or an arbitrator,
including for the purpose of substituting liens imposed on Indemnitee’s assets.

 

		1.3.	The Company’s obligation to indemnify Indemnitee and advance Expenses in accordance with
this Agreement shall be for such period as Indemnitee shall be subject to any actual, possible or threatened claim, action, suit,
demand or proceeding or any inquiry or investigation, whether civil, criminal or investigative, arising out of the Indemnitee’s
service in the Corporate Capacity as described in Section ‎1.1 above, whether or not Indemnitee is still serving in such
position (the “Indemnification Period).

 

		1.4.	The Company undertakes that, subject to the mandatory limitations under applicable law and the
Articles, as in effect from time to time, as long as it may be obligated to provide indemnification and advance Expenses under
this Agreement, the Company will purchase and maintain in effect directors’ and officers’ liability insurance, which
will include coverage for the benefit of the Indemnitee, providing coverage in amounts as reasonably determined by the Board; provided
that, the Company shall have no obligation to obtain or maintain directors and officers insurance policy if the Company determines
in good faith that such insurance is not reasonably available, the premium costs for such insurance are disproportionate to the
amount of coverage provided, or the coverage provided by such insurance is so limited by exclusions that it provides an insufficient
benefit. The Company hereby undertakes to notify the Indemnitee thirty (30) days prior to the expiration or termination of such
directors’ and officers’ liability insurance.

 

		1.5.	The Company undertakes to give prompt written notice of the commencement of any claim hereunder
to the insurers in accordance with the procedures set forth in each of the policies. The Company shall thereafter diligently take
all actions reasonably necessary under the circumstances to cause such insurers to pay, on behalf of Indemnitee, all amounts payable
as a result of such action, suit, proceeding, inquiry or investigation in accordance with the terms of such policies. The above
shall not derogate from Company’s authority to freely negotiate or reach any compromise with the insurer which is reasonable
at the Company’s sole discretion provided that the Company shall act in good faith and in a diligent manner.

 

		1.6.	In making a determination with respect to entitlement to indemnification hereunder, the person
or persons or entity making such determination shall presume that Indemnitee is entitled to indemnification under this Agreement
if Indemnitee has requested it, and the Company shall have the burden of proof to overcome that presumption in connection with
the making of any determination contrary to that presumption.

 

     

    - 4 -

    

 

		2.	SPECIFIC LIMITATIONS ON INDEMNIFICATION.

 

Notwithstanding anything to
the contrary in this Agreement, the Company shall not indemnify or advance Expenses to Indemnitee with respect to (i) any act,
event or circumstance with respect to which it is prohibited to do so under applicable law, or (ii) a counter claim made by the
Company or in its name in connection with a claim against the Company filed by the Indemnitee.

 

		3.	REPAYMENT OF EXPENSES.

 

		3.1.	In the event that the Company provides or is required to provide indemnification with respect to
Expenses hereunder and at any time thereafter the Company determines, based on advice from its legal counsel, that the Indemnitee
was not entitled to such payments, the amounts so indemnified by the Company will be promptly repaid by Indemnitee, unless the
Indemnitee disputes the Company’s determination, in which case the Indemnitee’s obligation to repay to the Company
shall be postponed until such dispute is resolved by a court of competent jurisdiction in a final and non-appealable order.

 

		4.	SUBROGATION.

 

In the event of payment under
this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who
shall execute all documents required and shall do everything that may be necessary to secure such rights, including the execution
of such documents necessary to enable the Company effectively to bring suit to enforce such rights.

 

		5.	REIMBURSEMENT.

 

The Company
shall not be liable under this Agreement to make any payment in connection with any Indemnifiable Event to the extent Indemnitee
has otherwise actually received payment under any insurance policy or otherwise (without any obligation of Indemnitee to repay
any such amount) of the amounts otherwise indemnifiable hereunder. Any amounts paid to Indemnitee under such insurance policy or
otherwise after the Company has indemnified Indemnitee for such liability or Expense shall be repaid to the Company as soon as
practical upon receipt by Indemnitee, in accordance with the terms set forth in Section ‎‎‎3.2.

 

The Company
hereby acknowledges that the Indemnitee has now or may have in the future certain rights to indemnification, advancement of expenses
and/or insurance provided by third parties (the “Third Party Indemnitor”), and the Company hereby agrees (i)
that the Company is the indemnitor of first resort (i.e., its obligations to the Indemnitee are primary and any obligation of any
Third Party Indemnitor to advance expenses or to provide indemnification for the same expenses or liabilities incurred by the Indemnitee
are secondary), (ii) it shall be required to advance the full amount of expenses incurred by the Indemnitee and shall be liable
for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement to the fullest extent legally permitted
and as required by the terms of this Agreement and/or the Articles (or any other agreement between the Company and the Indemnitee),
without regard to any rights the Indemnitee may have against the Third Party Indemnitors, and (iii) that it irrevocably waives,
relinquishes and releases any Third Party Indemnitor from any and all claims against any Third Party Indemnitor for contribution,
subrogation or any other recovery of any kind of respect of the subject matters of this Agreement. Without altering or expanding
any of the Company's indemnification obligations hereunder, the Company further agrees that no advancement or payment by any Third
Party Indemnitor on the Indemnitee's behalf with respect to any claim for which Indemnitee has sought indemnification from the
Company shall affect the foregoing and any Third Party Indemnitor shall have a right of contribution and/or be subrogated to the
extent of such advancement or payment to all of the rights of recovery of the Indemnitee against the Company. The Company and the
Indemnitee agree that the Third Party Indemnitors are express third party beneficiaries of the terms of this Section ‎5.

 

     

    - 5 -

    

 

		6.	EFFECTIVENESS.

 

The Company represents and
warrants that this Agreement is valid, binding and enforceable in accordance with its terms and was duly adopted and approved by
the Company, and shall be in full force and effect immediately upon its execution and shall continue to be in full force for the
duration of the Indemnification Period.

 

		7.	NOTIFICATION AND DEFENSE OF CLAIM.

 

Indemnitee shall notify the
Company of the commencement of any action, suit or proceeding, and of the receipt of any notice or threat that any such legal proceeding
has been or shall or may be initiated against Indemnitee (including any proceedings by or against the Company and any subsidiary
thereof), promptly upon Indemnitee first becoming so aware; but the omission to so notify the Company will not relieve the Company
from any liability which it may have to Indemnitee under this Agreement unless and to
the extent that such failure to provide notice materially and adversely impacts the Company’s ability to defend such action.
Notice to the Company shall be directed to the Chief Executive Officer or Chief Financial Officer of the Company at the address
shown in the preamble to this Agreement (or such other address as the Company shall designate in writing to Indemnitee). With respect
to any such action, suit or proceeding as to which Indemnitee notifies the Company of the commencement thereof and without derogating
from Sections ‎1.1 and ‎2:

 

		7.1.	The Company will be entitled to participate therein at its own expense.

 

		7.2.	Except as otherwise provided below, the Company, alone or jointly with any other indemnifying party
similarly notified, will be entitled to assume the defense thereof, with counsel selected by the Company. Indemnitee shall have
the right to employ his or her own counsel in such action, suit or proceeding, but the fees and expenses of such counsel incurred
after notice from the Company of its assumption of the defense thereof shall be at the expense of Indemnitee, unless: (i) the
employment of counsel by Indemnitee has been authorized in writing by the Company; (ii) the Company shall have, in good faith,
reasonably concluded that there may be a conflict of interest under the law and rules of attorney professional conduct applicable
to such claim between the Company and Indemnitee in the conduct of the defense of such action; or (iii) the Company has not
in fact employed counsel to assume the defense of such action within reasonable time, in which cases the reasonable fees and expenses
of Indemnitee’s counsel shall be at the expense of the Company. The Company shall not be entitled to assume the defense of
any action, suit or proceeding brought by or on behalf of the Company or as to which the Company shall have reached the conclusion
specified in (ii) above.

 

		7.3.	The Company shall not be liable to indemnify Indemnitee under this Agreement for any amounts or
expenses paid in connection with a settlement of any action, claim or otherwise, effected without the Company’s prior written
consent.

 

		7.4.	The Company shall have the right to conduct the defense as it sees fit in its sole discretion (provided
that the Company shall conduct the defense in good faith and in a diligent manner and that the Company and its counsel shall keep
the Indemnitee reasonably notified on a regular basis of all events in the action), including the right to settle or compromise
any claim or to consent to the entry of any judgment against Indemnitee without the consent of the Indemnitee, provided that, the
amount of such settlement, compromise or judgment does not exceed the Limit Amount (if applicable) and is fully indemnifiable pursuant
to this Agreement (subject to Section ‎1.2 of this Agreement) and/or applicable law, and any such settlement, compromise
or judgment does not impose any penalty or limitation on Indemnitee without the Indemnitee’s prior written consent. The Indemnitee’s
consent shall not be required if the settlement includes a complete release of Indemnitee, does not contain any admission of wrong-doing
by Indemnitee, and includes monetary sanctions only as provided above. In the case of criminal proceedings, the Company and/or
its legal counsel will not have the right to plead guilty or agree to a plea-bargain
in the Indemnitee’s name without the Indemnitee’s prior written consent. Neither the Company nor Indemnitee will unreasonably
withhold or delay its consent to any proposed settlement.

 

     

    - 6 -

    

 

		7.5.	Indemnitee shall fully cooperate with the Company and shall give the Company all information and
access to documents, files and to his or her advisors and representatives as shall be within Indemnitee’s power, in every
reasonable way as may be required by the Company with respect to any claim that is the subject matter of this Agreement and in
the defense of other claims asserted against the Company (other than claims asserted by Indemnitee), provided that the Company
shall cover all expenses, costs and fees incidental thereto such that the Indemnitee will not be required to pay or bear such expenses,
costs and fees.

 

		8.	NON-EXCLUSIVITY.

 

The rights of the Indemnitee
hereunder shall not be deemed exclusive of any other rights Indemnitee may have under the Articles, applicable law or otherwise,
and to the extent that during the Indemnification Period the indemnification rights of the then serving Indemnitees are more favorable
to such Indemnitees than the indemnification rights provided under this Agreement, Indemnitee shall be entitled to the full benefits
of such more favorable indemnification rights to the extent permitted by law.

 

		9.	PARTIAL INDEMNIFICATION.

 

If Indemnitee is entitled under
any provision of this Agreement to indemnification by the Company for some or a portion of the Expenses, judgments, fines or penalties
actually or reasonably incurred by Indemnitee in connection with any proceedings, but not, however, for the total amount thereof,
the Company shall nevertheless indemnify Indemnitee for the portion of such Expenses, judgments, fines or penalties to which Indemnitee
is entitled under any provision of this Agreement. Subject to the provisions of Section 5 above, any amount received by Indemnitee
(under any insurance policy or otherwise) shall not reduce the Limit Amount hereunder and shall not derogate from the Company’s
obligation to indemnify the Indemnitee in accordance with the provisions of this Agreement up to the Limit Amount, as set forth
in Section ‎1.2.

 

		10.	BINDING EFFECT.

 

This Agreement shall be binding
upon and inure to the benefit of and be enforceable by the parties hereto and their respective successors and permitted assigns
and their respective heirs, personal representatives, executors and administrators. In the event of a merger or consolidation of
the Company or a transfer or disposition of all or substantially all of the business or assets of the Company, the Indemnitee shall
be entitled to the same indemnification and insurance provisions as the most favorable indemnification and insurance provisions
afforded to the then-serving Office Holders of the Company. In the event that in connection with such transaction the Company purchases
a directors and officers’ “tail” or “run-off” policy for the benefit of its then serving Office Holders,
then such policy shall cover Indemnitee and such coverage shall be deemed to be in satisfaction of the insurance requirements under
this Agreement. This Agreement shall continue in effect during the Indemnification Period regardless of whether Indemnitee continues
to serve in a Corporate Capacity.

 

Any amendment to applicable
law adversely affecting the right of the Indemnitee to be indemnified, insured or released pursuant hereto shall be prospective
in effect, and shall not affect the Company’s obligation or ability to indemnify or insure the Indemnitee for any act or
omission occurring prior to such amendment, unless otherwise provided by applicable law.

 

     

    - 7 -

    

 

		11.	SEVERABILITY.

 

The provisions of this Agreement
shall be deemed severable and the invalidity or unenforceability of any provision shall not affect the validity or enforceability
of the other provisions hereof. If any provision of this Agreement, or the application thereof or any circumstance, is invalid
or unenforceable, (i) a suitable and equitable provision shall be substituted therefor in order to carry out, so far as may be
valid and enforceable, the intent and purpose of such invalid or unenforceable provision and (ii) the remainder of this Agreement
and the application of such provision or circumstances shall not be affected by such invalidity or unenforceability, nor shall
such invalidity or unenforceability affect the validity or enforceability of such provision, or the application thereof, in any
other jurisdiction.

 

		12.	NOTICE.

 

All notices and other communications
pursuant to this Agreement shall be in writing and shall be deemed provided if delivered personally, telecopied, sent by electronic
facsimile, email, reputable overnight courier or mailed by registered or certified mail (return receipt requested), postage prepaid,
to the parties at the addresses shown in the preamble to this Agreement, or to such other address as the party to whom notice is
to be given may have furnished to the other party hereto in writing in accordance herewith. Any such notice or communication shall
be deemed to have been delivered and received (i) in the case of personal delivery, on the date of such delivery, (ii) in the case
of telecopier or an electronic facsimile or email, one business day after the date of transmission if confirmation of receipt is
received, (iii) in the case of a reputable overnight courier, three business days after deposit with such reputable overnight courier
service, and (iv) in the case of mailing, on the seventh business day following that on which the mail containing such communication
is posted.

 

		13.	GOVERNING LAW; JURISDICTION.

 

This Agreement shall be governed
by and construed and enforced in accordance with the laws of the Grand Duchy of Luxembourg, without giving effect to the conflicts
of law provisions of those laws. The Company and Indemnitee each hereby irrevocably consent to the exclusive jurisdiction and venue
of the courts of Luxembourg-City for all purposes in connection with any action or proceeding which arises out of or relates to
this Agreement.

 

		14.	ENTIRE AGREEMENT AND TERMINATION.

 

This Agreement represents the
entire agreement between the parties and supersedes any other agreements, contracts or understandings between the parties, whether
written or oral, with respect to the subject matter of this Agreement. For the avoidance of doubt, it is hereby clarified that
nothing contained herein derogates from the Company’s right in its sole discretion, subject to applicable law and the Articles,
to indemnify Indemnitee post factum for any amounts the Indemnitee may be obligated to pay.

 

		15.	NO MODIFICATION AND NO WAIVER.

 

No supplement, modification
or amendment, termination or cancellation of this Agreement shall be binding unless executed in writing by both of the parties
hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions
hereof (whether or not similar) nor shall such waiver constitute a continuing waiver. Any waiver shall be in writing. The Company
hereby undertakes not to amend its Articles in a manner that will adversely affect the provisions of this Agreement.

 

		16.	ASSIGNMENTS; NO THIRD PARTY RIGHTS.

 

Neither party hereto may
assign any of its rights or obligations hereunder except with the express prior written consent of the other party. Nothing
herein shall be deemed to create or imply an obligation for the benefit of a third party, except as set forth in Section
 ‎5. Without limitation of the foregoing, nothing herein shall be deemed to create any right of any insurer that
provides directors’ and officers’ liability insurance, to claim, on behalf of Indemnitee, any rights
hereunder.

 

     

    - 8 -

    

 

		17.	INTERPRETATION; DEFINITIONS.

 

The obligations
of the Company as provided hereunder shall be interpreted broadly and in a manner that shall facilitate its execution, to the extent
permitted by law, and for the purposes for which it was intended.

 

Unless the
context shall otherwise require: words in the singular shall also include the plural, and vice versa; any pronoun shall include
the corresponding masculine, feminine and neuter forms; the words “include”, “includes” and “including”
shall be deemed to be followed by the phrase “without limitation”; the words “herein”, “hereof”
and “hereunder” and words of similar import refer to this Agreement in its entirety and not to any part hereof; all
references herein to Sections or clauses shall be deemed references to Sections or clauses of this Agreement; any references to
any agreement or other instrument or law, statute or regulation are to it as amended, supplemented or restated, from time to time
(and, in the case of any law, to any successor provisions or re-enactment or modification thereof being in force at the time);
any reference to “law” shall include any supranational, national, federal, state, local, or foreign statute or law
and all rules and regulations promulgated thereunder; any reference to a “day” or a number of “days” (without
any explicit reference otherwise, such as to business days) shall be interpreted as a reference to a calendar day or number of
calendar days; reference to month or year means according to the Gregorian calendar; reference to a “company”, “corporate
body” or “entity” shall include a, partnership, firm, company, corporation, limited liability company, association,
joint venture, trust, unincorporated organization, estate, or a government municipality or any political, governmental, regulatory
or similar agency or body, and reference to a “person” shall mean any of the foregoing or a natural person.

 

		18.	COUNTERPARTS.

 

This Agreement may be executed
in any number of counterparts, each of which shall be deemed an original and enforceable against the parties actually executing
such counterpart, and all of which together shall constitute one and the same instrument; it being understood that parties need
not sign the same counterpart. The exchange of an executed Agreement (in counterparts or otherwise) by facsimile or by electronic
delivery in pdf format shall be sufficient to bind the parties to the terms and conditions of this Agreement, as an original.

 

[SIGNATURE PAGE TO FOLLOW]

 

     

    - 9 -

    

 

IN WITNESS WHEREOF,
the parties, each acting under due and proper authority, have executed this Agreement as of the date first mentioned above, in
one or more counterparts.

 

	NeoGames S.A.
	 
	By:	 	 
	 	 	 
	Name and title:	 	 

 

	Indemnitee:
	 
	Name:	 	 
	 	 
	Signature:	 	 
	 	 
	Address:idya-ex101_656.htm

 

Exhibit 10.1

Amendment No. 1 to Agreement

(“Amendment No. 1”)

 

	
Amendment No. 1 Date:
	
September 23, 2020

	
 
	
 

	
 
	
 

	
Name of Original Agreement:
	
Clinical Trial Collaboration and Supply Agreement (the “Original Agreement,” and together with any previous amendments which may be described below, the “Agreement”)

	
 
	
 

	
Effective Date of Original Agreement:
	
March 11, 2020

	
 
	
 

	
Parties:
	
Pfizer Inc. (“Pfizer”) and Ideaya Biosciences, Inc.  (“Ideaya”)

 

WHEREAS, the parties hereto desire to amend, among other things, certain terms of the Agreement including certain definitions in the Agreement. 

 

NOW, THEREFORE, in order to accommodate the desired amendment(s), the parties hereby agree as follows:  

 

	
1.
	
Defined Terms.   Capitalized terms used but not defined herein shall have the respective meanings ascribed to such terms in the Agreement.

 

	
2.
	
Amendment(s) to the Agreement. 

 

	
 
	
2.1.
	
The definition of “Pfizer Compound” is revised to read, in its entirety, as follows:

 

“1.42“Pfizer Compound” means MEKTOVI (binimetinib) or a salt thereof, excluding, however, any generic version of binimetinib other than a generic version owned or controlled by Pfizer or its Affiliate and/or Xalkori (crizotinib) ) or a salt thereof, excluding, however, any generic version of crizotinib other than a generic version owned or controlled by Pfizer or its Affiliate, as applicable.”

 

	
 
	
2.2.
	
The definition of “Study” is revised to read, in its entirety, as follows:

 

“1.55 “Study” means the portion of the Global Phase 1 study in Metastatic Uveal Melanoma (MUM) and GNAQ/11-mutated Solid Tumors (non-MUM) pertaining to the clinical evaluation of the Ideaya Compound in combination with either or both of the Pfizer Compounds.”

	
 
	
2.3.
	
The definition of “ALK Inhibitor” is added as new Section 1.59, as follows: 

 

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

1

 

 

“1.59  “ALK Inhibitor” means any small or large molecule that inhibits the anaplastic lymphoma kinase enzyme (ALK).”

 

	
 
	
2.4.
	
Section 3.8 of the Agreement is revised to read, in its entirety, as follows:

 

“3.8 All Clinical Data, including raw data and results therein, generated under this Agreement shall be jointly owned by Pfizer and Ideaya.  It is understood and acknowledged by the Parties that positive Clinical Data could be used to obtain Regulatory Approvals or label changes for the Compounds.  In such event, the Parties will enter into good faith negotiations to determine a regulatory submission strategy for the Compounds.  Similarly, if either Party believes that reference to data from other studies of the other Party is necessary for such Party to obtain Regulatory Approvals or label changes for its Compound, the Parties will discuss in good faith appropriate terms for possible access to or right to reference such data for such purpose.  Except as explicitly provided in Sections 9.1 and 9.2, Ideaya covenants not to disclose any unpublished Clinical Data or other documentation prepared specifically for use in connection with the Study to any Third Party in connection with Ideaya’s independent research, development and/or commercialization of the Ideaya Compound in combination with Ideaya’s or its Affiliate’s or any Third Party’s MEK Inhibitor or ALK Inhibitor, and Pfizer covenants not to disclose any unpublished Clinical Data or other documentation prepared specifically for use in connection with the Study to any Third Party in connection with Pfizer’s independent research, development and/or commercialization of a Pfizer Compound in combination with Pfizer’s or its Affiliate’s or any Third Party’s PKC Inhibitor.”  

 

	
 
	
2.5.
	
Section 3.11 of the Agreement is revised to read, in its entirety, as follows:

 

“3.11Notwithstanding anything in this Agreement to the contrary, each Party acknowledges and agrees that the other Party may have present or future business activities or opportunities, including business activities or opportunities with Third Parties, involving MEK Inhibitors or ALK Inhibitors, in the case of Ideaya, or PKC Inhibitors, in the case of Pfizer, or other similar products, programs, technologies or processes.  Accordingly, each Party acknowledges and agrees that nothing in this Agreement shall be construed as a representation or inference that the other Party will not develop for itself, or enter into business relationships with other Third Parties regarding, any products, programs, studies (including combination studies), technologies or processes that are similar to or that may compete with the Combination or any other product, program, technology or process, including MEK Inhibitors, ALK Inhibitors or PKC Inhibitors, provided that the Clinical Data, Sample Testing Results, Jointly Owned Inventions, and Confidential Information are not used or disclosed in connection therewith in violation of this Agreement.”

 

	
 
	
2.6.
	
Section 10.1.4 of the Agreement is revised to read, in its entirety, as follows:

 

“10.1.4Pfizer shall have the first right to initiate legal action to enforce all Joint Patents against infringement, and to protect all Jointly Owned Inventions from misappropriation, by any Third Party where such infringement or misappropriation results 

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

2

 

 

from the development or sale of a MEK Inhibitor or ALK Inhibitor or to defend any declaratory judgment action relating thereto, at its sole expense.  In the event that Pfizer fails to initiate or defend such action within [***] days after being first notified of such infringement or misappropriation, Ideaya shall have the right to do so at its sole expense.  Similarly, Ideaya shall have the first right to initiate legal action to enforce all Joint Patents against infringement and to protect all Jointly Owned Inventions from misappropriation, by any Third Party where such infringement or misappropriation results from the development or sale of a PKC Inhibitor or to defend any declaratory judgment action relating thereto, at its sole expense.  In the event that Ideaya fails to initiate or defend such action within [***] days after being first notified of such infringement, Pfizer shall have the right to do so at its sole expense.  In the event that legal action to enforce Joint Patents will involve infringement or misappropriation resulting from the development or sale of a molecule or molecules that is/are or include(s) both a MEK Inhibitor and a PKC Inhibitor or an ALK Inhibitor and a PKC Inhibitor, the Parties shall work together to coordinate such action and shall, unless one Party elects not to pursue such legal action, share the costs and expenses of such litigation equally.  For clarity, if the alleged infringer is selling or intending to sell only one of a MEK Inhibitor, ALK Inhibitor or a PKC Inhibitor, then the foregoing obligation to share the costs and expenses of such litigation shall not apply.”

 

	
 
	
2.7.
	
Section 10.2 of the Agreement is revised to read, in its entirety, as follows:

 

“10.2Inventions Owned by Pfizer.  Notwithstanding Section 10.1, the Parties agree that all rights to Inventions relating solely to the Pfizer Compound, a MEK Inhibitor or an ALK Inhibitor are the exclusive property of Pfizer.  Pfizer shall be entitled to file in its own name relevant patent applications and to own resultant patent rights for any such Invention.  For the avoidance of doubt, any Invention generically encompassing the Pfizer Compound (and not any Ideaya proprietary compound including the Ideaya Compound) within its scope, even where the Pfizer Compound is not disclosed per se, is the exclusive property of Pfizer.”

 

	
 
	
2.8.
	
Appendix A of the Agreement is revised to read, in its entirety, as set forthing in Appendix A of this Amendment No 1.

 

	
 
	
2.9.
	
Appendix B of the Agreement is revised to read, in its entirety, as set forthing in Appendix B of this Amendment No 1.

 

	
3.
	
Ratification of the Agreement.  Except as expressly set forth in Article 2 above, the Agreement shall remain unmodified and in full force and effect.  The execution, delivery and effectiveness of this Amendment No. 1 shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of the parties to the Agreement, nor constitute a waiver of any provision of the Agreement.

 

	
4.
	
Counterparts. This Amendment No. 1 may be executed in any number of counterparts, each of which shall be an original instrument and all of which, when taken together, shall constitute one and the same agreement.

 

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

3

 

 

 

SIGNATURES IMMEDIATELY FOLLOWING ON NEXT PAGE

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

4

 

 

 

IN WITNESS WHEREOF, the duly authorized representatives of Pfizer and Ideaya have executed this Amendment No. 1 as of the date first above written.

 

	
Ideaya Biosciences, Inc.
	
 
	
Pfizer Inc.

	
 
	
 
	
 

	
By:
	
/s/ Yujiro Hata
	
 
	
By:
	
/s/ Chris Boshoff

	
 
	
 
	
 
	
 
	
 

	
Print Name:
	
Yujiro Hata
	
 
	
Print Name:
	
Chris Boshoff

	
 
	
 
	
 
	
 
	
 

	
Title:
	
President and Chief Executive Officer
	
 
	
Title:
	
SVP & Chief Development Officer

	
 

	
Date:
	
9/23/2020
	
 
	
Date:
	
9/23/2020

	
 
	
(Duly authorized)
	
 
	
 
	
(Duly authorized)

	
 
	
 
	
 
	
 
	
 

 

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

5

 

 

Appendix A

 

PROTOCOL SUMMARY

[***]

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

6

 

 

Appendix B– Supply Schedule

Supply of Compounds – Phase I/II Study combo with IDE196

 

Ideaya and Pfizer are entering into this Supply Schedule to define each Party’s clinical supply chain responsibilities with respect to the IDEYA Study pursuant to the Clinical Trial Collaboration and Supply Agreement dated March 11, 2020, as amended by Amendment No. 1 to Agreement dated September 23, 2020.

This Supply Schedule is to be used for contracting purposes between Ideaya and Pfizer and defines the responsibilities not covered in the Quality Agreement for the binimetinib Drug Product (“Binimetinib Compound”) and the crizotinib Drug Product (“Crizotinib Compound” and each a “Pfizer Compound”), clinical packaging/labeling, release, storage/distribution /control/disposal, import/export, and Interactive Response Technology (IRT), regulatory, forecast planning activities for the Ideaya Compound(s)/ binimetinib or Compound(s)/crizotinib and Ideaya combination clinical trials.

 

Upon approval, it will serve as the standard of operation between both parties for these clinical supply activities.

 

Ideaya will provide Pfizer written orders [***] days before delivery of the binimetinib Drug Product. Pfizer will provide Ideaya with binimetinib [***]. Pfizer is providing [***].

 

Ideaya will provide Pfizer written orders [***] days before delivery of the crizotinib Drug Product. Pfizer will provide Ideaya with [***].

 

Delivery timelines and Compound quantities are based on the Phase I/II study plan in place at the time of the Effective Date. Compound quantities are subject to modification based on Study conduct (due, for example, to the addition of Study sites or countries, patients with durable responses, etc). If the quantity of compounds set forth in this Agreement are not sufficient to complete the Study, Ideaya shall so notify Pfizer and the Parties shall discuss in good faith regarding additional quantities of Compounds to be provided and the schedule on which such additional quantities may be provided. 

 

As specified in the Collaboration Agreement, the Parties agree that Pfizer shall provide each Pfizer Compound for use in the Study at no cost to Ideaya. 

 

Following are estimates of the demand for the supply of the Pfizer Compound for the Study. The supply chain teams from Pfizer and Ideaya will meet regularly to review demand and supply requirements and adjust the delivery schedule to ensure continuous supply for the Study.

 

Study Assumptions

 

[***]

 

 

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

7

 

 

The source of the Compounds to be provided by the Parties during the Term may change.  In such event, the supplying Party will ensure that all Compounds supplied by such Party will be from an approved source and the table above will be updated as applicable Regulatory Authorities approve the change to the Manufacturing Site.

 

The responsibilities of both parties are summarised in table below:

 

CLINICAL SUPPLIES TABLE OF ROLES AND RESPONSIBILITIES

Documentation will be transferred between the Clinical Supply Chain contacts or designee.

[***]

 

This Supply Schedule is binding on the final date of approval.  The Supply Schedule can be reviewed at any time by mutual consent of each party to determine if changes will be considered minor or major.  Any minor changes to the content of the Supply Schedule will be documented in the Revision History box and no re-routing for signatures will be required.  A major change will necessitate the document to be revised, re-routed for signatures and be assigned the next sequential version number. 

 

IN WITNESS HEREOF, Ideaya and Pfizer hereby approves this Supply Schedule, Version 1 as of the dates set forth below: 

					
	
Ideaya Biosciences, Inc. 
	
 
	
Pfizer, Inc.

	

Signature
	
/s/ Yujiro Hata
	
 
	
Signature
	
/s/ Patrick Furcolo

	
 

Name
	
Yujiro Hata
	
 
	
Name
	
Patrick Furcolo

	
 

Title
	
President and Chief Executive Officer
	
 
	
Title
	
Director SupChainProjMgmt

	
 

Date
	
9/23/20
	
 
	
Date
	
9/23/20

 

 

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}]]